Logo image of ANL

ADLAI NORTYE LTD-ADR (ANL) Stock Fundamental Analysis

NASDAQ:ANL - Nasdaq - US00704R1095 - ADR - Currency: USD

2.3115  +0.09 (+4.12%)

Fundamental Rating

1

Taking everything into account, ANL scores 1 out of 10 in our fundamental rating. ANL was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of ANL have multiple concerns. ANL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ANL has reported negative net income.
In the past year ANL has reported a negative cash flow from operations.
ANL Yearly Net Income VS EBIT VS OCF VS FCFANL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

ANL has a Return On Assets of -97.39%. This is in the lower half of the industry: ANL underperforms 74.17% of its industry peers.
The Return On Equity of ANL (-196.51%) is worse than 68.06% of its industry peers.
Industry RankSector Rank
ROA -97.39%
ROE -196.51%
ROIC N/A
ROA(3y)-68.19%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANL Yearly ROA, ROE, ROICANL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 50 -50 -100 -150

1.3 Margins

ANL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANL Yearly Profit, Operating, Gross MarginsANL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

2

2. Health

2.1 Basic Checks

ANL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANL has less shares outstanding than it did 1 year ago.
ANL has a worse debt/assets ratio than last year.
ANL Yearly Shares OutstandingANL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M 40M 50M
ANL Yearly Total Debt VS Total AssetsANL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -5.52, we must say that ANL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.52, ANL is doing worse than 63.00% of the companies in the same industry.
ANL has a Debt/Equity ratio of 0.73. This is a neutral value indicating ANL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.73, ANL is not doing good in the industry: 76.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Altman-Z -5.52
ROIC/WACCN/A
WACC8.96%
ANL Yearly LT Debt VS Equity VS FCFANL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 1.85 indicates that ANL should not have too much problems paying its short term obligations.
ANL's Current ratio of 1.85 is on the low side compared to the rest of the industry. ANL is outperformed by 76.96% of its industry peers.
ANL has a Quick Ratio of 1.85. This is a normal value and indicates that ANL is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.85, ANL is not doing good in the industry: 75.39% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.85
ANL Yearly Current Assets VS Current LiabilitesANL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ANL have decreased strongly by -365.31% in the last year.
EPS 1Y (TTM)-365.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.07% on average over the next years. This is quite good.
The Revenue is expected to grow by 123.45% on average over the next years. This is a very strong growth
EPS Next Y69.66%
EPS Next 2Y29.72%
EPS Next 3Y18.37%
EPS Next 5Y19.07%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y123.45%

3.3 Evolution

ANL Yearly Revenue VS EstimatesANL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ANL Yearly EPS VS EstimatesANL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANL Price Earnings VS Forward Price EarningsANL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANL Per share dataANL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as ANL's earnings are expected to grow with 18.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.72%
EPS Next 3Y18.37%

More info and screens

0

5. Dividend

5.1 Amount

ANL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADLAI NORTYE LTD-ADR

NASDAQ:ANL (3/7/2025, 8:05:00 PM)

2.3115

+0.09 (+4.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.18%
Inst Owner Change-10.79%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap85.30M
Analysts80
Price Target9.18 (297.14%)
Short Float %0.01%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)45.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.06
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-5.14
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-1.81
FCFYN/A
OCF(TTM)-1.81
OCFYN/A
SpS0.14
BVpS1.45
TBVpS1.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -97.39%
ROE -196.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-68.19%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.62%
Cap/Sales 4.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.85
Altman-Z -5.52
F-ScoreN/A
WACC8.96%
ROIC/WACCN/A
Cap/Depr(3y)89.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-365.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.77%
EPS Next Y69.66%
EPS Next 2Y29.72%
EPS Next 3Y18.37%
EPS Next 5Y19.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y123.45%
EBIT growth 1Y-0.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.08%
EBIT Next 3Y-12.27%
EBIT Next 5YN/A
FCF growth 1Y-27.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.08%
OCF growth 3YN/A
OCF growth 5YN/A